GALAXY ENT (00027) announced that for the first quarter of 2026, the Group recorded net revenue of HKD 12.4 billion, representing an 11% increase year-on-year but a 10% decrease quarter-on-quarter. Adjusted EBITDA was HKD 3.6 billion, up 8% compared to the same period last year but down 17% from the previous quarter. The quarterly performance fluctuations were influenced by luck factors. In the fourth quarter of 2025, the Group's adjusted EBITDA was HKD 4.3 billion, which included an approximate increase of HKD 730 million due to a higher net win rate. However, in the first quarter, an approximate decrease of HKD 2 million was recorded due to a lower net win rate. Excluding the impact of win rates, adjusted EBITDA remained stable compared to the previous quarter. Business performance was robust during the Lunar New Year period, similar to last year, and remained strong after the holiday. GALAXY ENT maintains a healthy and highly liquid balance sheet, with cash and liquid investments totaling HKD 39.2 billion. This financial strength enables the Group to invest in future development, explore overseas opportunities, and return capital to shareholders through dividends. The previously proposed final dividend of HKD 0.80 per share by the Board of GALAXY ENT will be distributed in June 2026, reflecting the Group's continued confidence in the overall prospects of Macau, particularly in GALAXY ENT's longer-term outlook.